BD, Labcorp collaborate to develop flow cytometry-based companion diagnostics for matching patients with treatments

FRANKLIN LAKES, N.J., August 9, 2022 — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.

Four reasons to talk to your patients about colon cancer screening

More than 100 million people in the US are eligible for colon cancer screening, but why are so many of them not following through with testing?1,2 Misconceptions about colon cancer screening—including when it is appropriate and what testing methods are available—are among the leading reasons patients delay screening.3 You can help your patients follow through on their colon cancer screening by discussing their options and educating them on fecal immunochemical testing (FIT).